AppYea, Inc.

AppYea, Inc. operates as a digital health company that designs, patents, and produces sensor monitoring and software solutions for snoring and sleep apnea. It develops SleepX App, a smartphone application that uses unique algorithms to monitor breathing and detect snoring events in real time; DreamIT, a night wristband with various sensors and interfaces with the SleepX APP for treating snoring; SleepX PRO, a smartphone application that uses unique algorithms to monitor breathing and detect incidents of sleep apnea in real time; and DreamIT PRO, a wristband with various sensors and interfaces with the SleepX PRO app for the treatment of sleep apnea. The company was founded in 2012 and is based in Rehovot, Israel.

AppYea, Inc. trades as APYP on OTC. The company is classified in Technology / Software - Application and reports in USD.

The current profile places the business in Software - Application. This section is intended to summarize the operating segments, products, geographies, and main revenue lines from official filings.

Detailed operating-segment data is not available for this symbol yet.

Use this area for management strategy, capital allocation priorities, target markets, and measurable goals from the latest annual report or investor presentation.

The app now provides the structure, but exact strategic claims should come from official company documents before being treated as a finished investment thesis.

AppYea, Inc. can be compared against peers such as OSL Group Limited, Everything Blockchain, Inc., Elcom International Inc., Grow Capital, Inc., HUMBL, Inc., KwikClick, Inc..

A complete thesis should compare growth, margins, balance-sheet risk, valuation multiples, and market position against direct competitors.

Current signals to investigate include market capitalization of $6.12M, beta of 0.94, and return on equity of N/A.

This section should be validated with evidence such as durable margins, brand strength, regulation, switching costs, cost advantage, distribution, or technology.

Key risks should include financial leverage, cyclicality, customer concentration, regulatory exposure, currency risk, and execution risk.

APYP currently shows total debt of N/A and beta of 0.94. Missing data should be treated as a research gap, not as low risk.

Production-capacity detail is not available as structured data yet. For industrial, defense, semiconductor, or real-estate companies, this should be reviewed from annual reports and investor presentations.

No structured backlog field is available yet. If the company reports backlog, review the relevant filing section before adding it to the thesis.

Use this section for major contracts, product launches, construction projects, acquisitions, or strategic programs that can materially affect valuation.

No recent SEC-style filings are available for this symbol yet.

Customer concentration is not available as structured data here. Add it from official filings when a company discloses material customers or revenue concentration.

Supplier concentration and critical supply-chain dependencies are not available as structured data here. This should be researched from annual reports and risk disclosures.

Company website: https://www.sleepxclear.com

For Israeli stocks, verify official filings and local reports before publishing the thesis.